RU2015151175A - Способы улучшения липидных профилей с применением атрасентана - Google Patents
Способы улучшения липидных профилей с применением атрасентана Download PDFInfo
- Publication number
- RU2015151175A RU2015151175A RU2015151175A RU2015151175A RU2015151175A RU 2015151175 A RU2015151175 A RU 2015151175A RU 2015151175 A RU2015151175 A RU 2015151175A RU 2015151175 A RU2015151175 A RU 2015151175A RU 2015151175 A RU2015151175 A RU 2015151175A
- Authority
- RU
- Russia
- Prior art keywords
- subject
- level
- cholesterol
- relative
- atrasentan
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 40
- 150000002632 lipids Chemical class 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 21
- 238000008214 LDL Cholesterol Methods 0.000 claims 15
- 210000002966 serum Anatomy 0.000 claims 15
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 claims 13
- 229950010993 atrasentan Drugs 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 206010001580 Albuminuria Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361817645P | 2013-04-30 | 2013-04-30 | |
| US61/817,645 | 2013-04-30 | ||
| US201361824199P | 2013-05-16 | 2013-05-16 | |
| US61/824,199 | 2013-05-16 | ||
| PCT/US2014/036152 WO2014179453A1 (en) | 2013-04-30 | 2014-04-30 | Methods for improving lipid profiles using atrasentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015151175A true RU2015151175A (ru) | 2017-06-07 |
Family
ID=50928265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015151175A RU2015151175A (ru) | 2013-04-30 | 2014-04-30 | Способы улучшения липидных профилей с применением атрасентана |
Country Status (13)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3023102T (lt) | 2010-11-04 | 2018-09-25 | Albireo Ab | Ibat inhibitoriai, skirti kepenų ligų gydymui |
| KR20220082931A (ko) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| WO2021126977A1 (en) | 2019-12-17 | 2021-06-24 | Chinook Therapeutics, Inc. | Methods of treating iga nephropathy with atrasentan |
| CA3176465A1 (en) * | 2020-04-10 | 2021-10-14 | Chinook Therapeutics, Inc. | Methods of treating diabetic kidney disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2799241A (en) | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
| US3173876A (en) | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| NL271831A (cg-RX-API-DMAC7.html) | 1960-11-29 | |||
| US3276586A (en) | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US5286497A (en) | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
| US5573776A (en) | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5544163A (en) | 1994-03-08 | 1996-08-06 | Excel, Inc. | Expandable telecommunications system |
| US6162927A (en) | 1994-08-19 | 2000-12-19 | Abbott Laboratories | Endothelin antagonists |
| US5767144A (en) | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| AU6944296A (en) | 1995-09-13 | 1997-04-01 | Takeda Chemical Industries Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| CL2004000545A1 (es) * | 2003-03-18 | 2005-01-28 | Pharmacia Corp Sa Organizada B | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul |
| US9051301B2 (en) | 2004-09-17 | 2015-06-09 | Abbvie Inc. | Crystalline form of a drug |
| WO2006034084A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| US20060135596A1 (en) | 2004-09-17 | 2006-06-22 | Zhang Geoff G | Amorphous form of a drug |
| US20070004745A1 (en) * | 2005-03-25 | 2007-01-04 | Schering-Plough Corporation | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors |
| US20080132710A1 (en) | 2006-12-04 | 2008-06-05 | Abbott Laboratories | Atrasentan hydrochloride crystalline form 2 |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| CN101822837A (zh) * | 2010-02-02 | 2010-09-08 | 王丽燕 | 包含艾力沙坦酯盐的药物组合物 |
| MX2015011730A (es) | 2013-03-08 | 2016-04-04 | Abbvie Inc | Metodos para tratar la lesion renal aguda. |
-
2014
- 2014-04-30 US US14/888,195 patent/US9855245B2/en not_active Expired - Fee Related
- 2014-04-30 KR KR1020157033693A patent/KR20160003128A/ko not_active Withdrawn
- 2014-04-30 CN CN201480032387.7A patent/CN105246512A/zh active Pending
- 2014-04-30 SG SG11201508960SA patent/SG11201508960SA/en unknown
- 2014-04-30 EP EP14729532.3A patent/EP2991680A1/en not_active Withdrawn
- 2014-04-30 BR BR112015027631A patent/BR112015027631A2/pt not_active IP Right Cessation
- 2014-04-30 JP JP2016512012A patent/JP2016521279A/ja active Pending
- 2014-04-30 HK HK16110230.1A patent/HK1221916A1/zh unknown
- 2014-04-30 WO PCT/US2014/036152 patent/WO2014179453A1/en not_active Ceased
- 2014-04-30 RU RU2015151175A patent/RU2015151175A/ru not_active Application Discontinuation
- 2014-04-30 MX MX2015015036A patent/MX2015015036A/es unknown
- 2014-04-30 CA CA2909871A patent/CA2909871A1/en not_active Abandoned
- 2014-04-30 AU AU2014259961A patent/AU2014259961A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9855245B2 (en) | 2018-01-02 |
| CA2909871A1 (en) | 2014-11-06 |
| KR20160003128A (ko) | 2016-01-08 |
| US20160074363A1 (en) | 2016-03-17 |
| BR112015027631A2 (pt) | 2017-08-22 |
| WO2014179453A1 (en) | 2014-11-06 |
| EP2991680A1 (en) | 2016-03-09 |
| HK1221916A1 (zh) | 2017-06-16 |
| JP2016521279A (ja) | 2016-07-21 |
| AU2014259961A1 (en) | 2015-11-05 |
| CN105246512A (zh) | 2016-01-13 |
| SG11201508960SA (en) | 2015-11-27 |
| MX2015015036A (es) | 2016-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015151175A (ru) | Способы улучшения липидных профилей с применением атрасентана | |
| JP2016521279A5 (cg-RX-API-DMAC7.html) | ||
| Catapano et al. | Combination therapy in dyslipidemia: where are we now? | |
| MY199017A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| IL274403A (en) | Tyrosine hydroxylase inhibitors for the treatment of intestinal hypertension | |
| WO2012100229A3 (en) | Compositions and methods for cardiovascular disease | |
| MX378496B (es) | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina. | |
| JP2014516953A5 (cg-RX-API-DMAC7.html) | ||
| EA201690035A1 (ru) | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов | |
| WO2012177481A3 (en) | Fibroblast growth factor receptor inhibition for the treatment of disease | |
| RU2015110240A (ru) | Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия | |
| WO2011055944A3 (en) | Methods for treating fibromyalgia syndrome | |
| JP2016538254A5 (cg-RX-API-DMAC7.html) | ||
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| EA201291247A1 (ru) | ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ В ФОРМЕ ДВУХСЛОЙНЫХ ТАБЛЕТОК, СОДЕРЖАЩИХ ИНГИБИТОР HMG-CoA РЕДУКТАЗЫ И ИРБЕСАРТАН | |
| CL2013000513A1 (es) | Uso de una composicion farmaceutica que comprende: a) un compuesto monohidratado formado por dos aniones y un cation o b) valsartan y un etil-ester de acido, para el tratamiento de hipertension y/o la prevencion o el tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. | |
| DK1713458T3 (da) | Fremgangsmåde til forstærkning af biotilgængeligheden af ospemifen | |
| JP2007527433A5 (cg-RX-API-DMAC7.html) | ||
| EA200801008A1 (ru) | Гипохолестеринемические соединения | |
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| FI3821891T3 (fi) | FK506:n käyttö pulmonaarisen valtimohypertension hoidossa | |
| Dursun et al. | The anti-inflammatory and antioxidant effects of pravastatin and nebivolol in rat aorta | |
| EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
| EA202092397A3 (ru) | Фармацевтическая композиция для подавления образования кзкднк вируса гепатита в | |
| HK1204977A1 (en) | Treatment for high cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180813 |